Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:2051-2056
Published online before print September 2, 2004, doi: 10.1161/01.ATV.0000143858.15909.29
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/11/2051    most recent
01.ATV.0000143858.15909.29v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loike, J.D.
Right arrow Articles by Silverstein, S.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loike, J.D.
Right arrow Articles by Silverstein, S.C.
Related Collections
Right arrow Pathophysiology
Right arrow Cell signalling/signal transduction
Right arrow Lipid and lipoprotein metabolism
Right arrow Receptor pharmacology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:2051.)
© 2004 American Heart Association, Inc.


Vascular Biology

Statin Inhibition of Fc Receptor–Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol

J.D. Loike; D.Y. Shabtai; R. Neuhut; S. Malitzky; E. Lu; J. Husemann; I.J. Goldberg; S.C. Silverstein

From the Departments of Physiology and Medicine, Columbia University College of Physician and Surgeons, New York, NY.

Correspondence to J.D. Loike, Departments of Physiology and Medicine, Columbia University College of Physician and Surgeons, 630 W 168th St, New York, NY 10032. E-mail jdl5{at}columbia.edu

Objectives— An inflammatory response to altered lipoproteins that accumulate in the arterial wall is a major component of the pathogenesis of atherosclerosis. Statins reduce plasma levels of low-density lipoprotein (LDL) and are effective treatments for atherosclerosis. It is hypothesized that they also modulate inflammation. The aim of this study was to examine whether lovastatin inhibits macrophage inflammatory processes and clarify its mechanism of action.

Methods and Results— We examined the effects of statins on phagocytosis of antibody-coated red blood cells by cultured human monocytes and mouse peritoneal macrophages. Lovastatin, simvastatin, and zaragozic acid, a squalene synthase inhibitor, blocked Fc receptor–mediated phagocytosis by cultured human monocytes and mouse peritoneal macrophages. The inhibitory effect of lovastatin on Fc receptor–mediated phagocytosis was prevented completely by addition of mevalonate, farnesyl pyrophosphate, LDL, or cholesterol to the culture medium. The inhibitory effect of zaragozic acid was reversed by addition of LDL, but not by the addition of geranylgeranyl pyrophosphate, to the medium. In addition, the effect of lovastatin on phagocytosis is a function of cell activation because treatment of cells with tumor necrosis factor-{alpha} or lipopolysaccharide prevented inhibition of phagocytosis by lovastatin.

Conclusions— The inhibition of Fc receptor–mediated phagocytosis of lovastatin is related to its effect on cholesterol biosynthesis rather than its effect on the formation of isoprenoids.

An inflammatory response to altered lipoproteins that accumulate in the arterial wall is a major component of pathogenesis of atherosclerosis. Statins reduce plasma levels of low-density lipoprotein and are effective treatments for atherosclerosis. It is hypothesized that they also modulate inflammation. The aim of this study was to examine whether lovastatin inhibits macrophage inflammatory processes and clarify its mechanism of action.


Key Words: lovastatin • phagocytosis • cell activation • monocytes and macrophages




This article has been cited by other articles:


Home page
International Journal of ToxicologyHome page
N. Sakamoto, S. Hayashi, H. Mukae, R. Vincent, J. C. Hogg, and S. F. van Eeden
Effect of Atorvastatin on PM10-induced Cytokine Production by Human Alveolar Macrophages and Bronchial Epithelial Cells
International Journal of Toxicology, January 1, 2009; 28(1): 17 - 23.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
K. Haldar
Targeting the Host to Control an Infection Disorder
Arch Intern Med, October 27, 2008; 168(19): 2067 - 2068.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
P. Haberzettl, R. P. F. Schins, D. Hohr, V. Wilhelmi, P. J. A. Borm, and C. Albrecht
Impact of the Fc{gamma}II-receptor on quartz uptake and inflammatory response by alveolar macrophages
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1137 - L1148.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Morimoto, W. J. Janssen, M. B. Fessler, K. A. McPhillips, V. M. Borges, R. P. Bowler, Y.-Q. Xiao, J. A. Kench, P. M. Henson, and R. W. Vandivier
Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease.
J. Immunol., June 15, 2006; 176(12): 7657 - 7665.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. G. Kay, R. Z. Murray, J. K. Pagan, and J. L. Stow
Cytokine Secretion via Cholesterol-rich Lipid Raft-associated SNAREs at the Phagocytic Cup
J. Biol. Chem., April 28, 2006; 281(17): 11949 - 11954.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. B. Fessler, S. K. Young, S. Jeyaseelan, J. G. Lieber, P. G. Arndt, J. A. Nick, and G. S. Worthen
A Role for Hydroxy-Methylglutaryl Coenzyme A Reductase in Pulmonary Inflammation and Host Defense
Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 606 - 615.
[Abstract] [Full Text] [PDF]